Limits...
Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter.

Meier M, Mortensen FV, Madsen HH - Acta Radiol Open (2015)

Bottom Line: The technical success rate was 100%.Ten patients (50.0%) experienced minor adverse events.Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Section for Upper Gastrointestinal and Hepato-pancreatico-biliary Surgery, Aarhus University Hospital, Aarhus, Denmark.

ABSTRACT

Background: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested.

Purpose: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter.

Material and methods: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients' medical records, we retrieved data on patients and procedures.

Results: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days.

Conclusion: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.

No MeSH data available.


Related in: MedlinePlus

Frontal X-ray showing the abdominal peritoneal PleurX catheter.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4548747&req=5

fig2-2058460115579934: Frontal X-ray showing the abdominal peritoneal PleurX catheter.

Mentions: Twenty consecutive patients (14 women, 6 men) underwent permanent PleurX catheter implantation for MA (Fig. 2). Patient demographics are presented in Table 1.Fig. 2.


Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter.

Meier M, Mortensen FV, Madsen HH - Acta Radiol Open (2015)

Frontal X-ray showing the abdominal peritoneal PleurX catheter.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4548747&req=5

fig2-2058460115579934: Frontal X-ray showing the abdominal peritoneal PleurX catheter.
Mentions: Twenty consecutive patients (14 women, 6 men) underwent permanent PleurX catheter implantation for MA (Fig. 2). Patient demographics are presented in Table 1.Fig. 2.

Bottom Line: The technical success rate was 100%.Ten patients (50.0%) experienced minor adverse events.Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Section for Upper Gastrointestinal and Hepato-pancreatico-biliary Surgery, Aarhus University Hospital, Aarhus, Denmark.

ABSTRACT

Background: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested.

Purpose: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter.

Material and methods: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients' medical records, we retrieved data on patients and procedures.

Results: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days.

Conclusion: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.

No MeSH data available.


Related in: MedlinePlus